Therapeutics case studies

A sponsor needed to recruit nearly 500 patients for a pivotal study in an ultra rare disease. The study's demanding protocol posed significant difficulties for patients. ICON was able to revise the protocol, reducing patient burden, and implemented a global recruitment strategy and additional support that allowed recruitment to be completed ahead of schedule, saving the sponsor an estimated $700,000.

ICON provided a large pharma sponsor with consistent, accurate ECG and ECHO modality imaging, contributing to a breakthrough pulmonary arterial hypertension treatment.

Explore how we built a dedicated global infrastructure of functional hubs, reducing the cost per FTE by over 20% and resulting in 20% productivity savings.

An accelerated training program for Early Development Oncology CRAs was required to significantly increase the cohort of CRA talent across 7 countries globally.

A top ten pharmaceutical company needed clinical site support in an FSP model as it changed its pipeline to focus on complex oncology studies. The introduction of a Site Engagement Liaison delivered significant efficiencies and reduced risk.

A randomised, double-blind, placebo-controlled study on behalf of a biotechnology organisation to evaluate the safety, tolerability, and efficacy of the study drug in subjects with moderate to severe plaque psoriasis.

A pivotal phase 3 randomised, double-blind study to improve MASH and reduce progression to cirrhosis and/or hepatic decompensation, with high volumes of scans across two imaging modalities.

A large-pharma sponsor was looking for a medical imaging partner to support a four-year, phase 3 Multiple Myeloma study. This trial included 600 patients and 200 sites and required expedited start-up and turnaround times.

A large pharmaceutical sponsor required an accelerated medical imaging data delivery for regulatory submission on a phase 3 advanced and/or unresectable biliary tract carcinoma study that spanned 277 sites with 1,115 patients.

A biotech company sought ICON's help to analyse and report on a limited data set to demonstrate cardiovascular safety in a rare disease study.

A pharmaceutical sponsor contracted ICON to run a phase 3 trial for an amyotrophic lateral sclerosis (ALS) treatment that included a large patient population spanning 14 countries.

ICON partnered with a top biopharma in the clinical development of CAR T for patients with relapsed and/or refractory Multiple Myeloma (BCMA construct) and B-cell Lymphomas (CD19 construct).